Early research (Phase 1)Ended earlyNCT03292172
What this trial is testing
Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Who this might be right for
Advanced Ovarian CancerTriple Negative Breast Cancer
Hoffmann-La Roche 36